Ascendis Pharma Announces Positive Top-line Results from a Phase 2 Pediatric Study for the Treatment of Growth Hormone Deficiency
04-Aug-2015 -
Ascendis Pharma A/S announced positive top-line results from a six-month Phase 2 study to evaluate the safety and efficacy of once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, or GHD."We are extremely pleased with the top-line results ...
growth hormones
phase II studies